Skip to main content

Table 2 Comparison of CMR variables between anthracycline and control groups

From: Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines

Variable Anthracycline (n = 18) Control (n = 17) p value
LVEF (%) 62.4 ± 7.5 68.0 ± 4.6 0.012
LVEDV (ml) 135.8 ± 31.9 125.5 ± 38.3 0.395
LVESV (ml) 51.2 ± 16.3 40.3 ± 14.9 0.048
LVSV (ml) 84.5 ± 21.3 85.1 ± 25.4 0.932
LVM (g) 118.1 ± 23.6 111.6 ± 25.7 0.444
LVCM (g) 87.9 ± 20.4 83.2 ± 21.1 0.507
LVM/EDV (g/ml) 0.88 ± 0.13 0.92 ± 0.14 0.487
LVEDV index (ml/m2) 73.1 ± 16.1 70.2 ± 17.1 0.612
LVESV index (ml/m2) 27.5 ± 9.4 22.4 ± 7.1 0.085
LVSV index (ml/m2) 45.6 ± 10.7 47.8 ± 11.4 0.567
LVM index (g/m2) 63.7 ± 10.5 62.9 ± 9.9 0.823
LVCM index (g/m2) 47.5 ± 9.1 46.9 ± 8.5 0.841
RVEF (%) 63.7 ± 7.6 67.4 ± 6.8 0.143
RVEDV (ml) 132.3 ± 40.1 127.1 ± 40.5 0.701
RVESV (ml) 48.8 ± 19.8 42.9 ± 19.7 0.382
RVSV (ml) 83.4 ± 24.0 84.1 ± 23.3 0.933
RVEDV index (ml/m2) 70.7 ± 19.8 70.8 ± 18.3 0.994
RVESV index (ml/m2) 26.0 ± 10.5 23.4 ± 9.9 0.450
RVSV index (ml/m2) 44.6 ± 11.3 47.2 ± 10.2 0.479
Native T1 (ms) 1262.8 ± 35.5 1262.7 ± 31.4 0.991
ECV (%) 25.9 ± 0.35 25.6 ± 0.25 0.779
T2 (ms) 40.9 ± 2.4 40.6 ± 1.4 0.672
  1. Data expressed as mean ± standard deviation (SD) or n (%)
  2. LVEF left ventricular ejection fraction, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LVSV left ventricular stroke volume, LVM left ventricular mass, LVCM left ventricular cardiomyocyte mass [(1-ECV × LVM], RVEF right ventricular ejection fraction, RVEDV right ventricular end-diastolic volume, RVESV right ventricular end-systolic volume, RVSV right ventricular stroke volume, ECV extracellular volume fraction